|Dr. Richard Peters||Pres, CEO & Director||1.34M||N/A||1963|
|Ms. Jean M. Franchi||CFO & Treasurer||576.33k||N/A||1966|
|Dr. Anthony J. Sinskey||Co-Founder and Scientific Advisor||N/A||N/A||1940|
|Mr. Jeffrey A. Munsie||Gen. Counsel, Head of Corp. Operations & Sec.||N/A||N/A||1977|
|Geoffrey Grande C.F.A.||Sr. Director of Communications||N/A||N/A||N/A|
Merrimack Pharmaceuticals, Inc. operates as a clinical stage biopharmaceutical company that targets biomarker-defined cancers. The company is developing MM-310, an antibody-directed nanotherapeutic, which is in Phase I clinical trial to treat patients with solid tumors. Its preclinical product candidates include MM-401, an agonistic antibody targeting a novel immuno-oncology target; and MM-201, a stabilized agonist-Fc fusion protein targeting death receptors 4 and 5. The company has a collaboration and license agreement with Ipsen S.A. Merrimack Pharmaceuticals, Inc. was incorporated in 1993 and is headquartered in Cambridge, Massachusetts.
Merrimack Pharmaceuticals, Inc.’s ISS Governance QualityScore as of April 1, 2019 is 8. The pillar scores are Audit: 2; Board: 7; Shareholder Rights: 6; Compensation: 9.